Budgeting in the time of COVID-19
Author:
Open Access
- 1 August 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (15) , 1174-1175
Abstract
Projecting future drug expenses is never an easy task. This year, Tichy et al1 provide key projections that will be needed now more than ever. This year health systems will not only face unprecedented financial challenges due to the coronavirus disease 2019 (COVID-19) pandemic; they may also be facing operational challenges. The section of the ASHP Foundation’s 2020 Pharmacy Forecast report regarding “black swans” (rare events with serious consequences, as popularized by Taleb2) noted that few health-system pharmacy departments had a strategic planning process in place to successfully deal with such an event.3 Meeting the patient surge and drug shortage challenges posed by the COVID-19 pandemic in addition to planning for costly new pharmaceuticals will test even the most robust organizations.Keywords
This publication has 4 references indexed in Scilit:
- National trends in prescription drug expenditures and projections for 2020American Journal of Health-System Pharmacy, 2020
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysisThe Lancet Oncology, 2020
- ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health SystemsAmerican Journal of Health-System Pharmacy, 2019
- The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United StatesJournal of Managed Care & Specialty Pharmacy, 2017